Navigation Links
Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
Date:9/26/2007

ICAL is the clinical development of BUPIVACAINE SURGICAL IMPLANT when applied topically for the management of painful chronic and acute wounds, including ulcers of various etiologies and burns. Patients with such wounds can suffer severe pain, especially when the dressing is changed. It is anticipated that CollaRx BUPIVACAINE TOPICAL will provide long- acting analgesia between dressing changes and significantly reduce pain at the time of dressing change. In addition to the analgesia provided by the bupivacaine, the fibrillar collagen matrix is also expected to provide supplementary wound healing benefits, ultimately leading to accelerated wound closure.

About CollaGUARD(TM)

CollaGUARD is comprised almost entirely of purified type-I collagen protein and is clinically indicated in the US for the management of pressure ulcers, venous stasis ulcers, diabetic ulcers, first and second degree burns, partial and full thickness wounds, and superficial injuries. Unlike alginates, hydrogels and hydrocolloids used in other categories of advanced wound care products, collagen is a fully biodegradable and bioactive material with a pharmacological action that stimulates the natural wound healing process. In addition, CollaGUARD provides the barrier protection and transparency of film dressings, which allows the clinician to visually inspect and monitor the wound without removal.

About Innocoll, Inc.

Innocoll is a privately held, specialty pharmaceutical company focused on surgical and topical products. It develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen- based technologies, CollaRx(R) and Liquicoll(R). Innocoll 's lead product, Gentamicin Surgical Implant for the treatment and prevention of surgical site infections, is approved for sale in 49 countries and is entering phase 3 development in the US. In 2005, Innocoll acquired the worldwide marketing rights for this product from Essex Chemis AG, a
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. XTL Provides Update on Phase I Clinical Trial of XTL-2125
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
6. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
7. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
8. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
9. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- DATATRAK International, Inc. (OTCQX: DATA), a ... eClinical solutions for the clinical trials industry, ... 9.0 eClinical Software. This release advances ... service delivery and introduces two new mechanisms ... DATATRAK Learning Center(TM) and the DATATRAK Learning ...
(Date:12/16/2009)... AVAX Technologies, Inc. (Pink Sheets: AVXT) ("AVAX" or ... a bridge loan financing (the "2009 Financing") pursuant ... (the "Agreement") with Firebird Global Master Fund, Ltd., ... a convertible promissory note, due June 30, 2010, ... issued a warrant to purchase an aggregate of ...
(Date:12/16/2009)... RealMed has been ranked the ... 2009 Top 20 Best in KLAS ... RealMed is a dynamic revenue cycle management ... between healthcare providers and all ... specializing in vendor performance measurement in the ...
Breaking Medicine Technology:DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 2DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 3DATATRAK's eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM) 4AVAX Technologies, Inc. Closes Bridge Financing 2AVAX Technologies, Inc. Closes Bridge Financing 3AVAX Technologies, Inc. Closes Bridge Financing 4RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3Is hepatic differentiation of embryonic stem cells induced by valproic acid and cytokines 3F 61615 1No muss no fuss miniaturized analysis for complex samples developed 10786 1No muss no fuss miniaturized analysis for complex samples developed 10786 2No muss no fuss miniaturized analysis for complex samples developed 10786 3Extinct moa rewrites New Zealands history 10782 1Extinct moa rewrites New Zealands history 10782 2
... high eradication rates for the most common, ... REINACH, Switzerland, Oct. 26 Arpida ... two pivotal Phase III,clinical trials at the ... (ICAAC)/Infectious Diseases Society of America (IDSA) 46th,annual ...
... at ICAAC -, BRIDGEWATER, N.J., Oct. 26 ... 3, randomized, open-label, ongoing clinical,trial showed that 79 ... mg (two 400 mg tablets) with 100 mg ... (<50 copies/mL) at week 96,compared with 71 percent ...
Other Medicine Technology:Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 2Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 3Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 4Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 5Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 6Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 7Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 8
(Date:12/17/2009)... marketing techniques, life coaching company puts free i-phone & ... http://itunes.apple.com/us/app/attainment-life-management/id345691804?mt=8 . For the Free download. , ... ... -- Utah based Attainment Life Management & Coaching is ... everything in life simplified into one little hand held ...
(Date:12/16/2009)... 16 Austin,s Custom Tops , a ... with Ryan Gray and Hill Country Home Health, a ... Wednesday, December 9th. Fifty people showed up to cheer ... through platefuls of sliders in support of the local ... as a casual bet over who could eat the ...
(Date:12/16/2009)... December 16, 2009 -- Every year in the ... and 57,000 patients die of the disease, making it ... adults, after lung cancer. , As researchers and clinicians ... -- simultaneously generating thousands of studies producing more and ... researcher of cancer and genetics at Case Western Reserve ...
(Date:12/16/2009)... MDRX ) announced today that it will ... six months ended November 30, 2009 before the ... Allscripts management will host a conference call and ... information at 8:30 AM Eastern Standard Time that ... ,, Allscripts fiscal second quarter earnings will be ...
(Date:12/16/2009)... Institute will sponsor a new learning collaborative ... who serve individuals at risk of, or ... plan, medical home and other provider settings. ... webinars on topics, solutions and case studies ... improvement. Each webinar will include a brief ...
Breaking Medicine News(10 mins):Health News:Attainment Life Management & Coaching has just Debuted its Free Application for I-Phone and I-Touch Users 2Health News:Austin-Based Business Co-Sponsors Gastric Feat for Charity 2Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 2Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3
... - Exhibits Growth In All Existing Markets -, ... Bulletin Board: PMQC, PMQCU, PMQCW), the third largest long-term ... served. The,Company experienced growth across all four of its ... in the New York City,metropolitan area, as well as ...
... HCA Inc. announced,today that it had commenced a ... aggregate principal amount of its outstanding debt. The series,of ... offer (the "Notes"),are listed in the table below with ... conditions of the tender offer are described in an,Offer ...
... novel drug designed to lessen muscle damage from a heart ... Research Institute. Results of the study, available online and to ... Circulation, reflect the first time the drug has been tested ... the activity of an enzyme called delta protein kinase C ...
... CHAPEL HILL, N.C., Feb. 7 Selecting and ... a new,challenge for marketing leaders at pharmas and ... share similar,structure, composition, and responsibilities -- all detailed ... Best Practices, LLC., According to research findings, ...
... on Exercise (ACE) Research Proves Dance Dance ... Revolution (DDR) Can Be a Tremendous Workout, SAN DIEGO, ... that eliminate conventional hand controllers in favor of more,full-body interaction, ... to the test., The ACE commissioned research out of ...
... Brings Leading Clean Indoor Air and Health Advocates Together ... Indoor Air Quality, SOUTHBOROUGH, Mass., Feb. 7 Most ... did you know the Environmental,Protection Agency says levels of indoor ... occasionally even 100 times higher -- than outdoor air,pollution levels? ...
Other Medicine News:Health News:Chem Rx Surpasses 65,000 Residents Served 2Health News:HCA Announces Cash Debt Tender Offer 2Health News:HCA Announces Cash Debt Tender Offer 3Health News:HCA Announces Cash Debt Tender Offer 4Health News:HCA Announces Cash Debt Tender Offer 5Health News:HCA Announces Cash Debt Tender Offer 6Health News:Novel compound may lessen heart attack damage 2Health News:Pharmaceutical Product Commercialization & Governance Best Practices: Securing Talent for Highly-Effective Brand Teams 2Health News:Can a Video Game Make Your Kids More Fit? 2Health News:February is Designated as 'National Care About Your Indoor Air' Month 2Health News:February is Designated as 'National Care About Your Indoor Air' Month 3Health News:February is Designated as 'National Care About Your Indoor Air' Month 4
For the quantitative determination of direct & total bilirubin in serum. Modified Malloy-Evelyn Diazotization Method. Endpoint Reaction Product measured at 540 nm. Linearity: 20 mg/dl...
... first microplate spectrophotometer designed specifically to run ... week. With rugged hardware, proven optical performance ... barrier of traditional spectrophotometry to obtain results ... easily read up to eight, 1 cm ...
... The 1100RS Spectrophotometers ... economical. Great for use ... laboratories, including educational, clinical, ... Options include COD vial ...
Spectra 3000RS & Spectra 3000RSP are very precise instruments. They have a metal base structure, durable parts for long life use, and they are very easy to use and maintain....
Medicine Products: